Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
14 studies found for:    ( Phentermine AND Topiramate ) [TREATMENT] AND Obesity [DISEASE]
Show Display Options
Rank Status Study
1 Completed
Has Results
Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients
Condition: Obesity
Interventions: Drug: Phentermine-Topiramate ER;   Drug: Placebo
2 Completed Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
Condition: Obesity
Interventions: Drug: topiramate;   Drug: phentermine
3 Completed
Has Results
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
Condition: Obesity
Interventions: Drug: VI-0521;   Drug: topiramate;   Drug: phentermine
4 Withdrawn Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity
Conditions: Obesity;   Diabetes Mellitus
Interventions: Other: Behavioral and Drug;   Other: Behavioral
5 Completed
Has Results
Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults
Condition: Obesity
Interventions: Drug: VI-0521;   Drug: Placebo matched phentermine/topiramate
6 Completed
Has Results
A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)
Condition: Obesity
Interventions: Drug: VI-0521;   Drug: Placebo
7 Active, not recruiting A Toolbox Approach to Obesity Treatment in Primary Care
Condition: Obesity
Interventions: Behavioral: Commercial weight loss program;   Behavioral: Colorado Weigh;   Dietary Supplement: Meal replacements;   Drug: Obesity pharmacotherapy;   Behavioral: Recreation center passes
8 Completed Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
Condition: Obesity
Intervention: Drug: Qsymia
9 Not yet recruiting Qsymia as an Adjunct to Surgical Therapy in the Superobese
Conditions: Obesity;   Metabolic Surgery;   Weight Loss;   Bariatric Surgery Procedures
Intervention: Drug: Phentermine/topiramate
10 Completed A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
Condition: Obesity
Intervention: Drug: Metformin, VI-0521, Sitagliptan, Probenecid
11 Completed
Has Results
A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults
Condition: Sleep Apnea
Interventions: Drug: VI-0521;   Drug: placebo
12 Completed
Has Results
Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: VI-0521;   Drug: Placebo
13 Completed
Has Results
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
Conditions: Obesity;   Type 2 Diabetes
Intervention: Drug: VI-0521
14 Completed
Has Results
A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.
Conditions: Overweight;   Obesity
Interventions: Drug: VI-0521;   Drug: Placebo;   Other: Alcohol;   Other: alcohol placebo

Indicates status has not been verified in more than two years